Brilinta vs Xarelto
Side-by-side cost comparison based on Medicare Part D data
Brilinta
Ticagrelor
Manufactured by AstraZeneca
Xarelto
Rivaroxaban
Manufactured by Janssen
Brilinta costs 29% less per claim than Xarelto ($229.00 vs $321.00). A generic version of Brilinta is also available, which may reduce costs further.
Cost Per Claim
Medicare Spending
Beneficiaries
Annual Cost Per Patient
Full Comparison
| Metric | Brilinta | Xarelto |
|---|---|---|
| Avg Cost Per Claim | $229.00 | $321.00 |
| Total Medicare Spending | $567.0M | $5.0B |
| Total Beneficiaries | 298,000 | 1,920,000 |
| Total Claims | 2,480,000 | 15,680,000 |
| Annual Cost/Patient | $1,903.00 | $2,624.00 |
| Year-over-Year Change | -8.4% | -1.2% |
| Generic Available | Yes | Yes |
| Patent Expiration | Jan 31, 2023 | Jan 31, 2023 |
| Manufacturer | AstraZeneca | Janssen |
| Condition | Blood Clots | Blood Clots |
| Generic Name | Ticagrelor | Rivaroxaban |
Brilinta vs Xarelto: What the Data Shows
Brilinta (Ticagrelor) and Xarelto (Rivaroxaban) are both used to treat blood clots. Based on Medicare Part D data, Brilinta costs $229.00 per claim, which is 29% less than Xarelto at $321.00 per claim.
Medicare spent $567.0M on Brilinta and $5.0B on Xarelto. In terms of patient reach, Xarelto serves more beneficiaries (1,920,000 vs 298,000).
Year-over-year spending changed -8.4% for Brilinta and -1.2% for Xarelto.
Both drugs have generic versions available. Patients should discuss generic alternatives with their pharmacist to reduce out-of-pocket costs.
Frequently Asked Questions
Brilinta is cheaper at $229.00 per claim, compared to $321.00 for Xarelto. That makes Brilinta about 29% less expensive per claim based on Medicare Part D data.
Yes, both Brilinta and Xarelto are used to treat blood clots. Your doctor can help determine which medication is more appropriate for your specific situation.
Both drugs have generic versions available. Generic Ticagrelor and generic Rivaroxaban can offer significant cost savings — typically 80-95% less than the brand name.
Medicare Part D spent $567.0M on Brilinta covering 298,000 beneficiaries, and $5.0B on Xarelto covering 1,920,000 beneficiaries.
Explore Further
Cost data reflects Medicare Part D spending and may not represent retail pharmacy prices. Average cost per claim represents the total drug cost (not patient out-of-pocket) divided by total claims. This comparison is informational only and should not replace medical advice.